OVERVIEW PRESCRIBING WITH DUPLICATED NSAID THERAPY WITHOUT GASTRIC PROTECTIVE AGENTS AT A HOSPITAL IN INDONESIA

Adi Nurmesa, Abu Rachman, Wardatul Jannah

Abstract


Pain is a defence mechanism for the body that arises when the tissues in the body are being damaged. Pain therapy can be used in the form of NSAIDs. In prescribing NSAIDs, there is a risk of drug-related problems in the form of treatment duplication without gastroprotective. This study aims to determine the description of the type of duplication of NSAIDs without gastroprotective and explain pharmacist intervention efforts in reducing drug-related problems in prescribing NSAIDs. This retrospective observational study is conducted on all incoming prescriptions at the pharmacy satellite in March-June 2022 at one of the hospitals in Indonesia. The results of this study found 53 cases of duplication of NSAID therapy without gastroprotective from a total of 3,200 prescriptions, with the most duplication of NSAID therapy between Ibuprofen 400 mg and Mefenamic Acid 500 mg 24 cases. Pharmacist intervention in the form of clinical prescription screening is beneficial to avoid the risk of drug-related problems in prescribing NSAIDs.


Keywords


duplication of therapy; ibuprofen; gastric protective agents; mefenamic acid; NSAIDs

Full Text:

Download (PDF)

References


Guyton. Buku ajar fisiologi kedokteran. 11th ed. EGC. Jakarta: EGC; 2008.

Hidayati HB. Nyeri punggung bawah. Surabaya: Airlangga University Press; 2022. 105 p.

White WB, Cruz C. Impact of NSAIDs on cardiovascular risk and hypertension. Ital J Med. 2011;5(3).

Pawlosky N. Cardiovascular risk: are all NSAIDs alike? Can Pharm J. 2013;146(2).

Abdu N, Mosazghi A, Teweldemedhin S, Asfaha L, Teshale M, Kibreab M, et al. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): usage and co-prescription with other potentially interacting drugs in elderly: a cross-sectional study. PLoS One. 2020;15(10 October).

Nurmesa A, Jannah W, Rachman A. Risk factors for the incidence of overdose of Etoricoxib Drug in outpatient at a hospital in Indonesia. IJAClinPharm. 2024;1(1):37–43.

Koffeman AR, Valkhoff VE, Çelik S, ’T Jong GW, Sturkenboom MC, Bindels PJE, et al. High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. Br J Gen Pract. 2014;64(621):191–8.

Steinman MA, Miao Y, Boscardin WJ, Komaiko KDR, Schwartz JB. Prescribing quality in older veterans: a multifocal approach. J Gen Intern Med. 2014;29(10):1379–86.

Payne RA. The epidemiology of polypharmacy. Clin Med J R Coll Physicians London. 2016;16(5):465–9.

Bakhriansyah M, Souverein PC, van den Hoogen MWF, de Boer A, Klungel OH. Risk of nephrotic syndrome for non-steroidal anti-inflammatory drug users. Clin J Am Soc Nephrol. 2019;14(9):1355–62.

Schindler E, Richling I, Rose O. Pharmaceutical Care Network Europe (PCNE) drug-related problem classification version 9.00: German translation and validation. Int J Clin Pharm. 2021;43(3):726–30.

U.S Food & Drug Administration. FDA strengthens warning that non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes [Internet]. Food & Drug Administration. 2015. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory

Darini M. Peptic ulcer disease and non-steroidal anti-inflammatory drugs. Aust Prescr. 2017;40(3):91.

Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging and Disease. 2018;9(1):143.

De Groot NL, Spiegel BMR, Van Haalen HGM, De Wit NJ, Siersema PD, Van Oijen MGH. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components. Value Heal. 2013;16(5):769–77.

Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol. 2014;70(10):1159–72.

Raymond CB, Wazny LD, Sood AR. Standards of clinical practice for renal pharmacists. Can J Hosp Pharm. 2013;66(6):369.

Osoro I, Amir M, Vohra M, Sharma A. Pharmacist interventions in minimising drug-related problems in diabetes with co-existing hypertension: a five-year overview and ground report from India. Int J Public Health. 2023;68:1605808.

Shahrami B, Sefidani Forough A, Najmeddin F, Hadidi E, Toomaj S, Javadi MR, et al. Identifying drug-related problems followed by clinical pharmacist interventions in an outpatient pharmacotherapy clinic. J Clin Pharm Ther. 2022;47(7):964–72.




DOI: http://dx.doi.org/10.52434/jifb.v15i2.3179

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Visitor :

Web Analytics